Frontiers Health is back, bringing together healthcare innovators from around the world to exchange insights and discuss some ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it ...

Pfizer is already active in the protein degrader area, having partnered with Arvinas in a $2 billion-plus deal signed in 2021 ...

The pandemic served as a catalyst for a revolution in genomic surveillance for tracking pathogens. The technology proved ...

At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at ...

According to MeiraGTx, AAV-GAD is designed to reprogramme dysfunctional circuits in the Parkinson's brain through the local ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics ...

Researchers from Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center (BMC) reviewed cancer ...

The oncology landscape is evolving, with a marked rise in cancer incidence among young adults globally. This challenges the traditional view of cancer as primarily an ailment of the elderly. The ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

The proposal, unveiled at the government's International Investment Summit today is headlined by the creation of a UK biotech ...

Long-term considerations: While short-term forecasting remains a priority, forecasters also keep an eye on medium and ...